Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain
Yonghyun Yoon, Rowook Park, Jaehyun Shim, Junyoung Park, Jihyo Hwang, Jungyoun Kim, King Hei Stanley Lam, Teinny Suryadi, Anwar Suhaimi · 2026
Read Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain by Yonghyun Yoon, Rowook Park, Jaehyun Shim, Junyoung Park, Jihyo Hwang, Jungyoun Kim, King Hei Stanley Lam, Teinny Suryadi, Anwar Suhaimi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13257608.txt.
Introduction
Yonghyun Yoon leads a 2026 narrative review placing magnesium at the meeting point of vessels and nerves. The mineral supports hundreds of enzyme reactions and steadies vascular, metabolic, and neural balance. Low magnesium links to vessel lining failure, artery hardening, poor small-vessel flow, and nerve pain sensitivity.
Three domains are woven together: artery disease growth, ischemic limb pain from peripheral artery disease, and neuropathic pain control through NMDA receptor calming. Blood-brain barrier protection and inflammation control add to the nerve side. Diabetes and poor nutrition emerge as shared soil for deficiency and pain. The authors are careful to separate plausible mechanisms from proven treatment. Direct trial evidence for limb pain relief stays limited, so magnesium is framed as a status worth correcting, not a cure.
Catalog record
| CREATOR | Yonghyun Yoon, Rowook Park, Jaehyun Shim, Junyoung Park, Jihyo Hwang, Jungyoun Kim, King Hei Stanley Lam, Teinny Suryadi, Anwar Suhaimi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain Authors: Yonghyun Yoon, Rowook Park, Jaehyun Shim, Junyoung Park, Jihyo Hwang, Jungyoun Kim, King Hei Stanley Lam, Teinny Suryadi, Anwar Suhaimi Published: 2026 ABSTRACT Magnesium (Mg) is an essential divalent cation involved in more than 600 enzymatic reactions and plays a fundamental role in vascular, metabolic, and neural homeostasis. Although Mg is frequently discussed as an analgesic supplement, emerging evidence suggests that it acts as a neurovascular–metabolic modulator. Low magnesium status has been associated with endothelial dysfunction, atherosclerotic burden, impaired microcirculatory function, and overlapping ischemic and neuropathic pain phenotypes, although direct causal clinical evidence remains limited. This narrative review integrates mechanistic and clinical evidence across three intersecting domains: (1) the role of Mg in endothelial dysfunction, vascular calcification, and atherogenesis; (2) the contribution of Mg deficiency to ischemic pain through peripheral arterial disease and microcirculatory failure; and (3) the modulation of neuropathic pain through NMDA receptor antagonism, neuroinflammatory suppression, and maintenance of blood–brain barrier integrity. In populations with atherosclerosis, diabetes mellitus, or nutritional insufficiency, hypomagnesemia may serve as a unifying pathophysiological link connecting vascular injury to pain sensitization. The recognition of Mg not merely as an analgesic agent, but as a neurovascular interface regulator, may inform more comprehensive therapeutic strategies in chronic vascular and neuropathic pain syndromes. This review emphasizes nutritional magnesium status and biologically plausible mechanisms rather than presenting magnesium supplementation as an established treatment for vascular or neuropathic pain. The evidence is strongest for mechanistic vascular and neuropathic pathways, whereas direct clinical evidence for magnesium supplementation in PAD-related ischemic limb pain remains limited. 1. Introduction Magnesium (Mg) is the fourth most abundant mineral in the human body and the second most prevalent intracellular cation after potassium, functioning as a cofactor in over 600 enzymatic systems governing energy metabolism, nucleic acid synthesis, ion channel regulation, and neurotransmitter release [1,2]. A significant proportion of adults consume less than the recommended dietary allowance, which generally ranges from 310 to 420 mg/day depending on age and sex [3]. This latent deficiency state, often subclinical and undetected by routine serum measurements, carries substantial consequences for cardiovascular and neurological health [4]. The traditional clinical framing of Mg has been predominantly pharmacological, focusing on its use as a tocolytic, antiepileptic, or adjuvant analgesic administered intravenously in acute settings. However, this perspective fails to capture the broader biological significance of chronic, low-grade Mg deficiency as a contributor to atherosclerotic and neuropathic disease trajectories. Epidemiological data consistently demonstrate that low dietary Mg intake and low serum Mg are independently associated with hypertension, coronary artery calcification, peripheral arterial disease (PAD), stroke, and cardiovascular mortality [4,5]. Mechanistically, Mg deficiency promotes endothelial dysfunction, oxidative stress, vascular smooth muscle cell transdifferentiation, and neuroinflammation, pathophysiological processes that converge at the interface between vascular disease and pain [1,6]. Recent public health-oriented reviews have further emphasized that suboptimal magnesium status remains common across populations and is influenced by dietary patterns, chronic disease, medication use, and lifestyle-related factors, supporting the need to interpret magnesium deficiency not only as an individual biochemical abnormality but also as a broader nutritional and public health issue [7]. Pain in the context of atherosclerosis and its complications is heterogeneous in origin. Ischemic pain arising from impaired microcirculation in peripheral arterial disease represents a distinct phenotype from neuropathic pain complicating diabetic or ischemic neuropathy, yet both may share a common upstream driver in Mg deficiency. In patients with type 2 diabetes, a well-documented vicious cycle exists wherein hypomagnesemia worsens insulin resistance, which in turn reduces renal Mg reabsorption, further depleting systemic Mg stores [8]. This cycle simultaneously damages both the vasculature and peripheral nerves, creating the substrate for co-occurring ischemic and neuropathic pain. This narrative review seeks to reframe Mg within a neurovascular–metabolic paradigm, examining its roles across three interconnected domains: endothelial biology and atherogenesis, peripheral vascular ischemia and microcirculatory pain, and neuropathic pain sensitization through central and peripheral neuromodulatory mechanisms. Rather than treating these as separate topics, we propose that low Mg status may represent an integrating pathophysiological factor linking vascular injury to pain phenotypes in metabolically vulnerable populations. Review Scope and Literature Selection This narrative review was designed to synthesize mechanistic and clinical literature relevant to magnesium, vascular dysfunction, peripheral arterial disease, ischemic pain, and neuropathic pain. Literature searches were conducted in PubMed, Google Scholar, and the reference lists of relevant reviews and primary studies from database inception to May 2026. To improve transparency while maintaining the narrative-review design, the search process was organized into five topic-specific blocks: magnesium and vascular dysfunction/atherosclerosis; magnesium and peripheral arterial disease/ischemic pain; magnesium and neuropathic pain/NMDA receptor signaling; magnesium and neuroinflammation/blood–brain barrier integrity; and magnesium and diabetes, metabolic syndrome, or neuropathy. The searches identified 1044 records across these five topic-specific blocks: magnesium and vascular dysfunction/atherosclerosis, 211 records; magnesium and peripheral arterial disease/ischemic pain, 7 records; magnesium and neuropathic pain/NMDA receptor signaling, 113 records; magnesium and neuroinflammation/blood–brain barrier integrity, 65 records; and magnesium and diabetes, metabolic syndrome, or neuropathy, 648 records. After removal of 78 duplicate records, 966 unique records were screened for relevance. Eligible sources included peer-reviewed mechanistic studies, animal studies, observational studies, randomized clinical trials, systematic reviews, narrative reviews, clinical guidelines, and major nutritional reference sources addressing magnesium status, magnesium supplementation, vascular dysfunction, peripheral arterial disease, ischemic or neuropathic pain, or diabetes-related neurovascular complications. Studies were excluded if they were non-peer-reviewed conference abstracts, duplicate publications, focused on clinical contexts outside the scope of this review, did not primarily address magnesium or the target neurovascular outcomes, or lacked accessible methodological or outcome information. Based on these criteria and the conceptual scope of this narrative review, the most relevant mechanistic, translational, epidemiological, clinical, guideline, and nutritional reference sources were incorporated into the final narrative synthesis. Ultimately, 64 sources were included in the final review. This review does not aim to provide a comprehensive overview of all magnesium-related cardiovascular, metabolic, neurological, or pain conditions. Instead, it focuses on selected evidence relevant to the neurovascular consequences of low magnesium status and its potential contribution to overlapping ischemic and neuropathic pain phenotypes. Because the purpose of this article is conceptual integration rather than quantitative evidence synthesis, no formal meta-analysis was performed. Accordingly, this review should be interpreted as a narrative synthesis of mechanistic, translational, epidemiological, and clinical evidence rather than as a systematic review. An overview of the proposed framework linking chronic magnesium deficiency to vascular dysfunction, neural sensitization, metabolic dysregulation, and mixed neurovascular pain phenotypes is presented in Figure 1. 2. Magnesium Homeostasis and Assessment Total body Mg content in adults is approximately 24 g, of which approximately 60% resides in bone, 39% in muscle and soft tissues, and only about 1% in the extracellular compartment, including the plasma [3]. This distribution explains why serum Mg, the most commonly measured clinical parameter, is an unreliable indicator of total body Mg status. Serum Mg concentrations are tightly maintained within a reference range of 0.7–1.0 mmol/L through a coordinated balance of intestinal absorption, bone exchange, and renal excretion; deficits in intracellular or bone Mg can persist despite normal serum values [3,9]. The principal transporters governing cellular Mg homeostasis are the transient receptor potential melastatin channels (TRPM)6 and TRPM7 [8]. TRPM6 is predominantly